Rheumatology Update Europe 2023

Vienna & Virtual, 5 – 6 May 2023


med update europe GmbH

unbiased support by

Boehringer Ingelheim

Boehringer Ingelheim is driven by the desire to serve humankind by improving human and animal health. As a successful, family owned company BI plans in generations. They work together globally and with integrity.


Hosted Symposium:

A breath of fresh air: advances in screening, monitoring, and treatment of ILD in patients with CTD

Martin Aringer, Elisabeth Bendstrup, Philippe Dieudé

5 May 2023, 13:05 – 13:50

(click to attend during livestream, no registration necessary.)

GSK is a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. The company aims to positively impact the health of 2.5 billion people over the next 10 years. Their bold ambitions for patients are reflected in new commitments to growth and a step-change in performance.


CSL Vifor is a global leader in iron deficiency and nephrology and is committed to launching the next generation of therapies to truly address the full spectrum of kidney disease, with a focus on dialysis and rare disease.


Hosted Symposium:

ANCA-associated vasculitis – interdisciplinary viewpoints

Ludwig Erlacher, Rainer Oberbauer

6 May 2023, 12:35 – 13:20

(click to attend during livestream, no registration necessary.)

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com.

Galapagos is a fully integrated biotechnology company focused on discovering, developing, and commercializing innovative medicines. The company is committed to improving patients’ lives worldwide by targeting diseases with high unmet needs. Their R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Galapagos’ portfolio comprises discovery through to Phase 4 programs in immunology, oncology, and other indications. Their first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan.

Sponsorship Proposal

Partnership Opportunities

Contact us

If you have further questions please contact us directly:

Extra Features


Something that lasts…
Many of the Update lectures from the Rheumatology Update Europe will be available to view on-demand.
Sign up for free and view all of the lectures presented at the Rheumatology Update Europe. Free for registered delegates!

Christian Dejaco



Share your work…
The Rheumatology Update Europe gives young rheumatologists, and experienced ones, an excellent opportunity to present their recent research to an interested and knowledgeable audience. 

Scientific Board & Speakers